N,N'-dibenzylethanedithioamide is qualified as a pharma-grade active substance for solid oral and parenteral dosage conversion. The model designation is the chemical name together with the route-specific quality suffix “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable”; no single compendial monograph exists, so the release specification is built from ICH Q6A decision-tree principles, ICH Q3C, ICH Q3D, and the relevant USP general chapters. The molecular formula is C₁₆H₁₆N₂S₂, the relative molecular mass is 300.35 g/mol, and the structure contains two thioamide substituents on an ethanedithioamide backbone. The material is supplied as an anhydrous crystalline powder with a target assay of 98.0% to 102.0% on an anhydrous basis. Unlike technical-grade dithioamide products, this API grade is controlled for residual benzylamine, elemental impurities, endotoxin, and subvisible particulate matter; the oral and injectable suffix means that the same lot can be used for tablet or capsule manufacture only after the relevant route-specific specification is confirmed, because the parenteral specification is more restrictive in microbiological quality and particle size.

Specification, Identification, and Impurity Control Framework

Identification is performed by Fourier transform infrared spectroscopy per Ph. Eur. 2.2.24 and by X-ray powder diffraction to confirm polymorphic identity; HPLC relative retention time is used as a third identification. The assay method is reversed-phase high-performance liquid chromatography on a C18 column with a phosphate buffer/acetonitrile mobile phase; UV detection at 254 nm is used. Related substances are separated under gradient conditions and reported by area normalization; the acceptance criterion is not more than 0.10% for any individual unspecified impurity and not more than 1.0% total impurities. The specification includes loss on drying USP <731> not more than 0.5% and residue on ignition USP <281> not more than 0.1%. Residual solvents are measured by headspace gas chromatography USP <467>; the limits follow ICH Q3C option 1. Elemental impurities are tested by ICP-MS after closed-vessel microwave digestion according to USP <232>/<233>; acceptance is aligned with ICH Q3D for oral and parenteral routes. The parenteral route adds bacterial endotoxin USP <85>, sterility USP <71>, and subvisible particulate matter USP <788>.

ICP-MS calibration uses multi-element standards at 1.0, 5.0, 10.0, and 50.0 µg/L; instrument detection limits for cadmium, lead, arsenic, and mercury are set below 0.1 µg/L to ensure quantitation at the permitted daily exposure levels of ICH Q3D. The HPLC method is qualified for specificity, linearity over 50–150% of the assay concentration, accuracy, and solution stability; forced degradation studies expose the compound to acid, base, peroxide, heat, and light to demonstrate mass balance. Oxidative degradation produces sulfoxide and sulfone impurities; these degradation products are separated from the parent peak and reported under the related substances test. Residual benzylamine is controlled by a suitable chromatography method with derivatization or charged aerosol detection; the limit is justified using the permitted daily exposure. Batch-to-batch variance in particle size and impurity profile is controlled by milling and by monitoring the sulfoxide/sulfone ratio. If the sulfoxide content increases above 0.10% during storage, the lot is rejected for parenteral use because oxidative impurities can contribute to subvisible particle formation and may alter solubility.

Solid oral conversion studies begin with particle-size reduction because the needle-like crystal habit of the unprocessed material limits flow and die filling. The active is air-jet milled or pin milled to a D90 of 75 μm for tablet and capsule work; when dissolution rate is critical, a D90 of 30 μm or below is used. Particle-size distribution is measured by laser diffraction per USP <429>. The milled powder is discharged into a stainless-steel bin blender with vessel loading at 60–80%; lactose monohydrate and microcrystalline cellulose are added as fillers, croscarmellose sodium as disintegrant, and magnesium stearate as lubricant. The blending time is 3–5 min after lubrication to avoid over-lubrication. Powder flow is assessed by the methods of USP <1174>; an angle of repose above 40° typically requires dry granulation or a glidant. If the angle is below 30°, capsule filling can proceed without granulation.

Dry granulation is performed with a roller compactor using a roll pressure of 20–50 kN and a gap of 1.0–2.0 mm; the ribbons are milled through a 1.0 mm screen. Dry granules have less surface area than wet-granulated material and may reduce the risk of hydrolytic degradation. Wet granulation is normally avoided because water accelerates oxidation of the thioamide group; if wet granulation is required, ethanol or isopropanol is used as the granulating solvent instead of purified water. In a high-shear granulator with impeller speed 250–350 rpm and chopper speed 1500 rpm, the binder solution is sprayed at a rate of 2–5 mL/min. Drying is carried out in a fluid-bed dryer at inlet air temperature 50–60 °C, with product temperature maintained below 40 °C to minimize sulfoxide formation. The dried granulate is milled through a 0.8–1.0 mm screen and lubricated before tableting.

Tablet compression is performed on a rotary press with compaction force monitoring, using 10 mm round tooling. The target hardness is 5–10 kp for a 200 mg tablet; this range must be verified because published data for this specific configuration is limited. Sticking and picking on steel tooling are controlled by maintaining relative humidity below 60% in the compression suite and by using a lubricant. Dissolution testing follows USP <711> with 0.1 N hydrochloric acid and phosphate buffer pH 6.8; the acceptance criterion is 75% dissolved in 45 min unless product-specific justification is established. Capsule filling is performed on an automatic capsule-filler with tamping stations; fill weight variation is controlled to ±5% for a 100 mg dose and ±3% for doses above 250 mg. Granule formulations for sachet or suspension are filled into single-dose containers; the product is protected from oxygen by aluminum foil overwrap with desiccant.

What process conflicts arise when a sulfur-containing thioamide is converted to an injectable dosage form?

The parenteral route introduces three conflicts: low aqueous solubility, oxidative degradation in aqueous solution, and sterilization. The dibenzylated molecule is hydrophobic; solubility should be measured in water, buffer, and co-solvent systems according to USP <1236>. If the measured solubility is below 1 mg/mL, a co-solvent system of propylene glycol and polyethylene glycol 400 or ethanol is used. The pH is maintained between 4.0 and 7.0 unless forced degradation data demonstrate adequate stability at more extreme pH. The solution should be deoxygenated by nitrogen sparging because thioamide oxidation is accelerated by dissolved oxygen. Terminal sterilization at 121 °C for 15 min is not recommended unless thermal stability data show that assay loss and total degradation products remain within specification; otherwise aseptic processing is used. The bulk solution is pre-filtered through a 0.45 μm membrane, then sterile-filtered through a 0.22 μm PVDF membrane with a validated filter integrity test. The filtrate is filled into Type I borosilicate glass vials under Grade A conditions; the headspace is blanketed with nitrogen before closure. The final sterile product is tested for sterility USP <71>, bacterial endotoxin USP <85>, and particulate matter USP <788>; the subvisible particulate limits for small-volume injectables are 6000 particles ≥10 μm and 600 particles ≥25 μm per container. Because published data for this specific configuration is limited, formulation development should use a design-of-experiments approach with assay, pH, and subvisible particulate matter as responses.

For lyophilized formulations, the API is dissolved in a co-solvent system, filled, and freeze-dried; the cycle should include freezing at -40 °C, primary drying at -20 °C, and secondary drying at 20–25 °C. Lyophilization reduces hydrolytic degradation because the material is stored in the solid state. The cake is injected after reconstitution; the reconstitution time should be less than 3 min under gentle swirling. Container closure integrity is tested by USP <1207>; dye ingress or vacuum decay may be used. The oxygen-sensitive nature of the thioamide requires that the final container moisture be less than 1.0% and oxygen headspace less than 2.0%.

Long-term storage follows ICH Q1A conditions. The API is packaged in a double polyethylene bag placed inside an aluminum foil laminate with desiccant; nitrogen headspace is used to reduce oxidative degradation. Storage temperature is maintained at 25 °C/60% RH for long-term and 40 °C/75% RH for accelerated; ICH Q1A intermediate conditions are applied if necessary. The container is opened only in low-humidity suites because moisture ingress above 60% RH requires pre-drying before processing. Photostability testing follows ICH Q1B; the compound should be protected from light because thioamides can undergo photochemical cleavage. The retest period is assigned from real-time stability data; if no real-time data exist for the specified configuration, the material is released with a provisional retest date and monitored quarterly.

When N-benzyl substitution is compared with unsubstituted dithiooxamide and other di-substituted derivatives

The N-benzyl groups differentiate this compound from unsubstituted dithiooxamide in lipophilicity, solubility, and crystalline packing. Unsubstituted dithiooxamide has two primary amide-like thioamide groups and dissolves more readily in polar media; the dibenzyl derivative has two aromatic rings that increase molecular mass, reduce water solubility, and increase solubility in ethanol, acetone, and dimethylformamide. This changes the pharmaceutical processing route: tablets and capsules may require micronization and a wetting agent such as sodium lauryl sulfate at 0.5–2.0% w/w to achieve acceptable dissolution; injectables may require co-solvent or lyophilized presentation. Compared with N,N'-dimethylthiooxamide, the benzyl substituent increases retention time on reversed-phase HPLC and alters the melting point; the exact melting point for this compound should be confirmed by differential scanning calorimetry USP <891>. Because published data for this specific configuration is limited, no comparative release-rate or bioavailability claim is made without product-specific testing.

Compared with technical-grade dithioamide intermediates, the pharma-grade material differs in analytical control. The technical product may be supplied without a residual solvent monograph, with variable particle size, and without endotoxin or sterility data; the pharma-grade API has a defined particle-size range, an impurity profile, an ICH Q3D elemental-impurity report, and route-specific microbial quality. This allows a single API grade to support oral tablet, capsule, and granule development as well as injectable development, provided that the lot meets the parenteral bacterial endotoxin and subvisible particulate limits and that any formulation-specific solubility or sterilization limits are separately validated.